Anti-Rheumatic Drugs - China | Statista Market Forecast

The projected revenue for this market in China is estimated to reach US$3.02bn in 2024.
Furthermore, it is anticipated that the market will experience a steady annual growth rate of 1.34% from 2024 to 2029.
This growth trajectory is expected to result in a market volume of US$3.22bn by 2029 in China.
When compared globally, United States is projected to generate the highest revenue in the Anti-Rheumatic Drugs market.
In 2024 alone, the revenue United States is estimated to reach a staggering US$34.70bn.
This showcases the dominance and significance of the US market in this market.
China's position in the Anti-Rheumatic Drugs market highlights its growing importance and potential as a major player in the global pharmaceutical industry.
With its vast population and increasing healthcare needs, in China presents a lucrative market for pharmaceutical companies operating in this market.
As in China continues to invest in healthcare infrastructure and improve access to quality medical treatments, the demand for Anti-Rheumatic Drugs market is expected to rise significantly in the coming years.
China's growing middle class and aging population are driving increased demand for anti-rheumatic drugs in the country.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The market for Anti-Rheumatic Drugs in China has been growing steadily in recent years.

Customer preferences: Chinese patients suffering from rheumatoid arthritis and other related diseases are increasingly opting for Anti-Rheumatic Drugs due to their effectiveness in managing symptoms such as pain, inflammation, and joint damage. With an aging population and rising income levels, patients are willing to spend more on healthcare and are seeking better treatment options.

Trends in the market: The market for Anti-Rheumatic Drugs in China is being driven by the increasing prevalence of rheumatoid arthritis and related diseases. Additionally, the availability of new and innovative drugs is contributing to the growth of the market. Biologic drugs, which are made from living organisms, are becoming increasingly popular due to their effectiveness in treating the disease. However, these drugs are often expensive and may not be covered by insurance, making them less accessible for some patients.

Local special circumstances: China's healthcare system is heavily regulated, with the government playing a significant role in the pricing and distribution of drugs. This has led to challenges for foreign pharmaceutical companies looking to enter the market. Additionally, there is a lack of awareness about rheumatoid arthritis and related diseases among the general population, which can lead to delayed diagnosis and treatment.

Underlying macroeconomic factors: China's aging population and rising income levels are contributing to the growth of the Anti-Rheumatic Drugs market. Additionally, the government's focus on improving healthcare access and quality is driving demand for better treatment options. However, the high cost of some drugs and the regulatory environment pose challenges for foreign companies looking to enter the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.